Logo

clonoSEQ® and you

Jump to

Why clonoSEQ?

Gain confidence in your future with clonoSEQ

clonoSEQ (pronounced clo-no-seek) is the first and only FDA-cleared test that detects, counts, and tracks MRD in blood or bone marrow samples from patients with chronic lymphocytic leukemia (CLL) and bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL).[1]

With clonoSEQ, you and your doctors can:

Graph showing changes in disease over time

MONITOR

your cancer by assessing treatment response and detecting changes in disease[1]

clonoSEQ supports shared decision making in blood cancer

MANAGE

decisions with an ongoing understanding of your long-term outcomes[1]

Moving forward with confidence

MOVE FORWARD

with confidence when planning for all of life’s moments[1]

Because clonoSEQ can detect one single cancer cell among a million healthy cells (provided sufficient sample material), you and your doctor can be confident you know if residual disease is detectable in your sample after each clonoSEQ test.[1]

From your clonoSEQ report, your doctor can determine whether your MRD status is positive (detectable disease) or negative (undetectable disease).

References to “cancer” on this webpage refer specifically to CLL, multiple myeloma, and B-ALL. References to “sample” refer to bone marrow or blood from patients with CLL and bone marrow from patients with multiple myeloma or B-ALL. Talk to your doctor about your options if you have another type of blood cancer and are interested in MRD testing.

A clonoSEQ journey

Understanding the clonoSEQ Patient Journey

Graph showing decreasing disease burden

How does clonoSEQ work?

clonoSEQ identifies the specific DNA sequence(s) associated with your cancer and tracks them over time.[1]

Throughout your treatment journey, samples can be collected periodically in order to monitor changes in your disease.

Graph showing changes in disease over time

Monitor your cancer by assessing treatment response and detecting changes in disease[1]

With clonoSEQ, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment. clonoSEQ MRD results, along with other clinical information, may even help your doctor to more accurately predict your long-term outcomes and tailor your care to respond to changes in your disease level.[2-5]

Setting a goal of reaching MRD negativity may be right for some patients. Talk with your doctor to find out if it’s right for you.

clonoSEQ supports shared decision making in blood cancer

Manage decisions with an ongoing understanding of your long-term outcomes[1]

While remission is a relief for many patients, it may be accompanied by a feeling of uncertainty. Therefore, your doctor can use clonoSEQ to see if any cancer cells are returning.[1]

Regular MRD assessment can help you and your care team feel confident in understanding your cancer and how your disease burden is changing over time. This way, you can be prepared when making decisions for both your treatment and personal life.

Moving forward with confidence

Move forward with confidence when planning for all of life’s moments[1]

Even if you aren’t experiencing any symptoms, you may still feel anxious or worried that the cancer will return. Routine MRD testing may help detect the return of cancer before physical signs and symptoms arise.[6,7]

Early detection of returning cancer may allow you and your doctor to respond quickly to fight your disease, so you can confidently plan for what the future has in store for you.

Where Your Cancer Stands

Can knowing your MRD status help you manage decisions along your cancer journey?

  • CLL

  • MULTIPLE MYELOMA

  • B-ALL

Monitoring MRD to detect changes in your disease can show how well your treatment is working. Knowing your MRD status, together with other clinical information, can help inform future decisions at key points in your care, such as:

  • Following first-line therapy[8,9]
  • Deciding whether to start maintenance therapy[10]
  • During maintenance therapy[11]
  • Detecting returning disease[5]
  • Throughout the course of relapsed/refractory therapy[12,13]

If you have CLL, talk with your doctor about clonoSEQ to begin pinpointing where you are with your disease and come up with a plan that works for you.

Explore stories from patients like you

Monitoring MRD to detect changes in your disease can show how well your treatment is working. Knowing your MRD status, together with other clinical information, can help inform future decisions at key points in your care, such as:

  • Following induction and consolidation therapy[4,14]
  • After stem cell transplant[15]
  • During and after completion of maintenance therapy[16]
  • Detecting returning disease with routine MRD testing[17]
  • Throughout the course of relapsed/refractory therapy[18]

If you have multiple myeloma, talk with your doctor about clonoSEQ to begin pinpointing where you are with your disease and come up with a plan that works for you.

Explore stories from patients like you

Monitoring MRD to detect changes in your disease can show how well your treatment is working. Knowing your MRD status, together with other clinical information, can help inform future decisions at key points in your care, such as:

  • Following induction and consolidation therapy[3,19]
  • After stem cell transplant[2]
  • During maintenance therapy[20]
  • Detecting returning disease with routine MRD testing[2]

If you have B-ALL, talk with your doctor about clonoSEQ to begin pinpointing where you are with your disease and come up with a plan that works for you.

Explore stories from patients like you

If you have CLL, multiple myeloma, or B-ALL, talk with your doctor about tracking your MRD status with clonoSEQ today.

Questions to ask your doctorPhysician Finder


This page is intended for a US-based audience.

clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). IGHV testing is also available as a CLIA-validated LDT. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

Citations

  • clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020. https://clonoseq.com/technical-summary.
  • Pulsipher M, et al. Blood. 2015;125(22):3501-3508.
  • Wood B, et al. Blood. 2018;131(12):1350-1359.
  • Perrot A, et al. Blood. 2018;132(23):2456-2464.
  • Thompson P, et al. Blood. 2019;134(22):1951-1959.
  • Sherrod A, et al. Bone Marrow Transplant. 2015;51:2-12.
  • NCI Dictionary of Cancer Terms: Complete Remission. National Cancer Institute. Accessed November 17, 2017.
  • Dimier N, et al. Blood. 2018;131(9):955-962.
  • Munir T, et al. Blood. 2017;130(Suppl 1):3013.
  • Molica S, et al. Clin Lymphoma Myeloma Leuk. 2019;19(7):423-430.
  • Kater A, et al. Blood Adv. 2018;2(24):3566-3571.
  • Hillmen P, et al. J Clin Oncol. 2019;37(30):2722-2729.
  • Fraser G, et al. Leukemia. 2019;33(4):969-980.
  • Martinez-Lopez J, et al. Blood Adv. 2020;4(14):3295-3301.
  • O’Dwyer M, et al. Blood Adv. 2019;3(12):1815-1825.
  • Voorhees P, et al. Blood. 2020;136(8):936-945.
  • Mateos M, et al. Lancet. 2020;395(10218):132-141.
  • Bahlis N, et al. Leukemia. 2020;34:1875-1884.
  • Berry DA, et al. JAMA Oncol. 2017;3(7):E1-9.
  • Raff T, et al. Blood. 2007;109(3):910-915.